Tag: Lord Mancroft

The below Parliamentary question was asked by Lord Mancroft on 2015-12-16.

To ask Her Majesty’s Government what steps they are taking to ensure that NHS England and Public Health England provide data demonstrating that there is equitable access to the new hepatitis C treatment.

Lord Prior of Brampton

Public Health England is working with NHS England and the Clinical Leads of the Operational Delivery Networks to ensure that a minimum data set is collected to allow monitoring of patients being treated. Limited demographic information will be requested to help interpret this information in the context of the whole infected population to help assess whether treatment access is as equitable as possible.

The below Parliamentary question was asked by Lord Mancroft on 2016-03-23.

To ask Her Majesty’s Government what plans they have to ensure that the objectives of the hepatitis C improvement framework can still be achieved.

Lord Prior of Brampton

NHS England has been rapidly working on their plans for access to treatment during 2016/17 following enactment of the National Institute for Health and Care Excellence technical appraisal guidance and has committed to produce an operational framework for the treatment of hepatitis C during 2016/17. This will set out NHS England’s commitment to improving outcomes in hepatitis C across England.

The below Parliamentary question was asked by Lord Mancroft on 2015-12-16.

To ask Her Majesty’s Government how they plan to measure the effectiveness of the implementation of the new medicines for hepatitis C treatment, and when they will publish those results.

Lord Prior of Brampton

NHS England has advised that it is working with Public Health England and the clinical leads of the operational delivery networks to agree a common dataset which will enable the effectiveness of new medicines for hepatitis C to be measured.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government on which specific NICE guidance NHS England based its decision to restrict access to new treatments for hepatitis C to 10,000 patients in 2016–17.

Lord Prior of Brampton

The planning approach for hepatitis C is set out in the National Institute for Health and Care Excellence (NICE) Technology Appraisals 363, 364 and 365 which require Operational Delivery Networks to prioritise treatment for patients with the highest unmet clinical need. We understand from NHS England that the figure of 10,000 patients reflects NICE modelling used for its recommendations and published alongside the guidance.

The below Parliamentary question was asked by Lord Mancroft on 2016-02-09.

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 January (HL4665) about access to hepatitis C treatment, how frequently NHS England will publish reports on the minimum data set and when the first set of data on patients being treated will be published.

Lord Prior of Brampton

Public Health England (PHE) is working with NHS England and the Clinical Leads of the Operational Delivery Networks to ensure that a minimum data set is collected to allow monitoring of patients being treated. This will be used to support commissioning and planning of these services. PHE plans to publish summary data on people being treated in the annual report on hepatitis C. No timetable for publication has been agreed.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government whether NHS England’s decision to treat 10,000 hepatitis C patients represents a cap on the number of patients the NHS can treat in 2016–17.

Lord Prior of Brampton

NHS England’s approach paces the roll-out of hepatitis C treatment in accordance with the National Institute for Health and Care Excellence (NICE) recommendation for prioritisation and the modelling assumptions which informed the NICE recommendations.

The below Parliamentary question was asked by Lord Mancroft on 2016-02-09.

To ask Her Majesty’s Government what steps they are taking to develop prison health workers’ understanding of the prevention, diagnosis and treatment of hepatitis C.

Lord Prior of Brampton

NHS England, Public Heath England, the National Offender Management Service and other organisations including the Royal College of General Practitioners have developed resources to support prison healthcare teams in delivering a blood-borne virus (BBV) opt-out testing programme. This covers all aspects of prevention, diagnosis and treatment of hepatitis C (HCV) and other BBVs including testing, managing positive and negative test results, providing advice on harm minimisation and supporting prisoners into treatment.

Specialised HCV Operational Delivery Networks (ODNs) ensure specialist oversight of HCV services in order maximise uptake and completion of HCV treatment. NHS England has linked every prison to the relevant ODN and a service specification for ODNs directs specialist service providers to accept patients from prisons.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government whether patients who meet the eligibility criteria for NICE-approved medicines for hepatitis C will have access to treatment in line with their rights under the NHS Constitution in 2016–17, even if more than 10,000 patients have already been treated.

Lord Prior of Brampton

NHS England’s approach paces the roll-out of hepatitis C treatment in accordance with the National Institute for Health and Care Excellence (NICE) recommendation for prioritisation and the modelling assumptions which informed the NICE recommendations. These are in line with patients’ rights under the NHS Constitution.

The below Parliamentary question was asked by Lord Mancroft on 2016-02-09.

To ask Her Majesty’s Government what progress Operational Delivery Networks have made in establishing services for prisoners diagnosed with hepatitis C.

Lord Prior of Brampton

NHS England, Public Heath England, the National Offender Management Service and other organisations including the Royal College of General Practitioners have developed resources to support prison healthcare teams in delivering a blood-borne virus (BBV) opt-out testing programme. This covers all aspects of prevention, diagnosis and treatment of hepatitis C (HCV) and other BBVs including testing, managing positive and negative test results, providing advice on harm minimisation and supporting prisoners into treatment.

Specialised HCV Operational Delivery Networks (ODNs) ensure specialist oversight of HCV services in order maximise uptake and completion of HCV treatment. NHS England has linked every prison to the relevant ODN and a service specification for ODNs directs specialist service providers to accept patients from prisons.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government on what basis, if any, the NHS Mandate requires that investment in NICE-recommended treatments for hepatitis C be limited to avoid disinvestment in other health services.

Lord Prior of Brampton

The NHS Mandate requires healthcare expenditure to be limited to the resources made available by the government. The range of potential treatments which could improve patients health exceeds the funding made available to the National Health Service, therefore increased investment in one area has an opportunity cost on the ability to invest in other areas. NHS England is investing in the rollout of Hepatitis C treatment in full accordance with National Institute of Health and Care Excellence guidance, with an expected doubling of the number of patients benefiting from new treatment to 10,000s in the coming year.